Background: 3-hydroxy-3-methylglutaryl coenzyme A reductase reductase inhibitors (statins) are generally well tolerated, with statin-associated muscle symptoms (SAMS) the most common side effect (~10%) seen in statin users. However, studies and clinical observations indicate that many of the self-reported SAMS appear to be nonspecific (ie, potentially not attributable to statins). Objective: Mental health and well-being influence self-perception of pain, so we sought to assess the effect of baseline well-being and depression on the development of muscle pain with 6 months of atorvastatin 80 mg/d (ATORVA) or placebo in healthy, statin-naive adults. Methods: The Psychological General Well-being Index (n = 83) and Beck Depression Inventory (n = 55) questionnaires were administered at baseline in participants (aged 59.5 T 1. , and pain severity (BPI) were then measured before, throughout, and after treatment. Results: At baseline, there were no differences in well-being (Psychological General Well-being Index), depression (Beck Depression Inventory), or pain measures (SF-MPQ and BPI) (P values Q .05) between the placebo and ATORVA groups. Baseline well-being correlated negatively with baseline BPI pain severity (r = j0.290, P = .008). Baseline depression correlated with baseline pain (SF-MPQ; r = 0.314, P = .020). Baseline well-being and depression did not predict the change in pain severity or interference after 6 months among the total sample or between groups (P values Q .05). Conclusion: Baseline well-being and depression were not significant predictors of pain after 6 months of ATORVA (P values Q .05). Thus, they do not appear to increase the risk of SAMS in otherwise healthy adults.
C ardiovascular disease (CVD) is the leading cause of death in the United States, affecting 1 in 3 (or 81.1 million) adults. 1 Lowering low-density lipoprotein cholesterol (LDL-C) by 1 mmol/L through lifestyle or pharmacological intervention reduces CVD-related events by 22%. 2 Hydroxy-methyl-glutaryl 3-hydroxy-3-methylglutaryl coenzyme A reductase reductase inhibitors, or statins, are the most effective pharmacologic therapy to lower LDL-C levels as they have the potential to decrease LDL-C level up to 60% and lower overall CVD risk by~50%. 3 In addition, 25% of Americans 45 years or older are currently prescribed a statin, making statins the most widely prescribed drugs in the United States and the world.
Statins are generally well tolerated; however, patient surveys indicate that 30% to 62% of statin-prescribed patients discontinue therapy because of muscle fatigue, weakness, and muscle pain complaints. 5Y7 Incidence of statin-associated muscle symptoms (SAMS) ranges widely from 10% to 25% in nonYindustry-funded clinical trials 8Y10 to 60% in observational studies. 5 In addition, recent studies indicate that 30% to 50% of patients with SAMS actually experience nonspecific muscle pain, that is, pain unrelated to the statin drug. 9, 11, 12 Therefore, it difficult to diagnose and treat SAMS, identify statin users who may be at risk for SAMS before therapeutic initiation, and effectively treat CVD with statins. 13 Although the pathological mechanisms underlying SAMS are not well understood, 13 differences in psychosocial characteristics of statin users may affect the frequency of SAMS such that individuals who are more depressed may feel more pain. For example, patients with fibromyalgia-like symptoms are 3 times more likely to have SAMS, whereas treatment with antidepressants for 3 months of more reduces SAMS by 50%. 8 These results suggest that mental health may influence self-perception of pain and may contribute to the high incidence of nonspecific muscle pain in statin users. Therefore, we sought to assess the effect of psychological health on muscle pain before and after 6 months of atorvastatin 80 mg/d (ATORVA) or placebo in healthy, statin-naive adults. ''Psychological health'' was operationalized in the present study through measurement of well-being and depression. We hypothesized that lower levels of well-being and higher levels of depression at baseline would result in higher muscle pain severity and pain interference with quality of life (QoL) after statin therapy.
Methods

Study Overview
The present study is part of a larger clinical trial, ''The Effect of Statins on Skeletal Muscle Function and Performance,'' of which the methods have previously been published in detail (Statins on Skeletal Muscle Function and Performance [STOMP]; NIH R01HL081893-01A2). 9, 14 The STOMP trial was the first randomly assigned, double-blinded study designed to examine the incidence of SAMS. Statin-associated muscle symptom was defined as pain that was new unexplained, persisted, went away upon 2 weeks of statin dechallenge, and resumed upon 4 weeks of statin rechallenge.
14 Briefly, 420 statin naive, healthy men and women were randomized to atorvastatin 80 mg (ATORVA) or placebo for 6 months. At baseline, a subset of patients from the larger STOMP trial (n = 83) were administered questionnaires to determine whether baseline depression and psychological well-being were related to SAMS (Figure 1 ). This subset represents those enrolled in the present study. The Hartford Hospital Institutional Review Board approved the study protocol (IRB THOM002069HE), and written informed consent was obtained from all participants.
Measures
Psychological Well-being The Psychological General Well-being Index (PGWB) is a 22-item, validated questionnaire that produces a self-perceived evaluation of psychological well-being expressed by a summary score ranging from 0 (poor) to 110 (good) 15 and 6 affective states: anxiety (range, 0Y25), depressed mood (range, 0Y14), sense of positive well-being (range, 0Y20), self-control (range, 0Y15), general health (range, 0Y15), and vitality (range, 0Y20). Higher scores on each of the relative ranges within the 6 affective states indicate ''low''/''good'' subgroup scores, whereas low scores indicate ''high''/''poor'' subgroup scores. For example, higher ranges within the anxiety state (range, 0Y25) indicate ''not bothered by nerves; low tension; not anxious,'' whereas lower scores indicate ''extremely bothered; very tense; and anxious''. The PGWB is a commonly used and validated questionnaire to measure well-being and QoL in both the general population and in special populations with an internal consistency of .94 and high internal reliability of .92 to .96. 16, 17 The 6 affective states also have been shown to have high internal reliability, with a retest reliability of .80 to .92. 16, 17 Depression The Beck Depression Inventory (BDI) is a 21-question assessment of depression severity that produces a summary score ranging from 0 to 63, with cutoff points used to indicate the severity level of depression. 18 A summary score higher than 20 on the BDI is considered clinical depression, whereas a summary score lower than 13 indicates minimal depression. The BDI is one of the most widely used, validated instruments for the detection of depression in general populations, with an internal consistency of .9 and retest reliability of .73 to .96. 19 
Statin-Associated Muscle Symptoms
Muscle pain was quantified at baseline and on a biweekly basis throughout the study through administration of standardized questionnaires. The Brief Pain Inventory (BPI) is a 9-item measure of pain severity and the extent in which pain interferes with QoL. 20 A pain severity score is calculated by averaging scores on 4 pain-intensity items, and a pain interference score is calculated by averaging scores on 7 pain interference items to determine the extent to which the muscle pain interferes with 2 domains of daily functioning: activity (ie, general activity, walking ability, normal work) and affective (ie, mood, relations with other people, sleep, enjoyment of life). Although the BPI was originally developed to assess cancer-related pain, it has been validated for use with nonmalignant pain populations and is used widely used in both clinical and research settings. In noncancer patients, BPI has a high reliability, ranging from .82 to .95, and high sensitivity to change among patients with arthritis (based on Wilks 1; F 4, 194 = 4.84, P = .001). 21 Participants also completed questionnaires before and after 6 months of treatment to assess muscle complaints using the Short-Form McGill Pain Questionnaire (SF-MPQ), which quantifies present pain intensity using both visual analog and categorical scales. 22 The SF-MPQ is one of the most commonly used research tools in the measure of pain, with a reliability ranging from .83 and .84. 21 
Statistical Analyses
Differences in baseline characteristics between placebo and ATORVA groups were assessed with a 1-way analysis of variance with significance set at P G .05. Data are reported as mean T SD. Bivariate correlations were run to test for significant relationships between wellbeing, depression, and pain before and after 6 months of treatment versus placebo. Repeated measures analysis of covariance tested between-group differences in the change of pain measures at 6 months from baseline with sex and drug assignment as a fixed factor and baseline pain, age, and psychological health measures (ie, PGWB and BDI) as covariates. Logistic regression tested the relationship between pain (severity or interference) as a binary outcome variable and depression or well-being as the independent predictor. Binary variables were created by coding patients as meeting the study definition of SAMS described above (study overview) or no SAMS. Furthermore, to capture any incremental changes in pain from baseline, but that did not meet the study definition of SAMS, binary variables were created by coding patients as having ''any pain'' (ie, any changes in pain after 6 months from baseline 91.0 of a possible 10 on the BPI scale) or ''no pain.'' All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 22.0 program for Windows (SPSS Inc, Chicago, Illinois).
Results
The total sample for this analysis (n = 83) included healthy men (n = 38) and women (n = 45) who were, on average, middle aged, overweight, with optimal blood lipoproteins and blood pressure (Table 1) .
23Y25
On average, participants had relatively low levels of depression (mean BDI, 4.4 T 4.5) and high levels of psychological well-being (mean PGWB, 88.6 T 15.9). Among the total sample, 1 patient was prescribed an antidepressant and/or antianxiety medication (ie, clozapine). At baseline, there were no between-group differences in overall well-being (PGWB), affective subgroups of well-being, depression (BDI), or pain measures (SF-MPQ and BPI) ( Table 2 ; P values Q .05).
Baseline well-being (PGWB) correlated with baseline pain severity (BPI; r = j0.290, P G .01) and several activity and affective subcomponents, including, enjoyment, walking ability, and general activity (P values G .03). Of the 6 affective subgroups of well-being, general health correlated with baseline pain severity (r = j0.593, P = .000) and interference (r = j0.380, P = .001), whereas vitality correlated with baseline pain severity (r = j0.288, P = .009) and trended toward correlating with interference (r = j1.94, P = .085). Baseline depression correlated with baseline pain (SF-MPQ; r = 0.313, P = .020), but not interference (P = .414).
Overall well-being was not correlated with pain at 6 months among the entire sample (P = .432); however, baseline general health correlated with pain severity and interference at 6 months among the entire sample (r = j0.384, P = .000 and r = j0.349, P = .001, respectively). Baseline depression was not correlated with pain at 6 months among the entire sample or by group (P values 9 .432). Both groups experienced an increase in pain after 6 months (placebo, 1.0 T 0.2 to 1.3 T 0.3; ATORVA, 1.0 T 0.2 to 1.8 T 0.3; P G .05 for time effect); however, there were no differences between groups (P = .270, time Â group interaction). Neither baseline depression, well-being, or general health was a significant covariate associated with pain or pain interference among the entire sample or by group (Figure 2 ; P values 9 .698 for group Â time effect). Even when applying logistic regression analyses to capture a low threshold of pain as a dichotomous variable (ie, pain vs no pain), baseline psychological health indicators (ie, depression; BDI and psychological well-being; PGWB) were not significant predictors of change in pain after 6 months irrespective of group (Figure 3 , P = .301). Similarly, baseline depression and well-being were not significant predictors of documented SAMS (SAMS vs no SAMS) in a logistic regression model (P = .297).
Discussion
To the best of our knowledge, the present study is the first to examine the influence of baseline well-being and depression on self-reported muscle pain after initiation statin therapy. Poor baseline psychological health has been implicated in the onset and/or exacerbation of other health conditions such as hypertension, 26 metabolic syndrome, 27 CVD, 28 mild cognitive impairment, 29 and general pain. 30 However, in the present study, baseline well-being and depression were not significant predictors of pain change after 6 months of ATORVA and do not appear to be associated with SAMS in otherwise healthy adults.
Psychosocial Health and Pain
The prevalence of pain as a symptom of diagnosed depression has been shown to be as high as~60%, 31 with severity of depression positively associated with intensity of pain. 32 Beneficial improvements in psychological well-being after cognitive behavioral therapy are associated with reduced pain sensitivity and severity. 33 Previous research has focused on the physiological mechanisms underlying SAMS 34 ; consequently, the biopsychosocial influence of statinassociated muscle pain has been overlooked. By contrast, other similar muscle-related syndromes, such as fibromyalgia, are more recognized on the biopsychogenic continuum and are often treated successfully with the use of antidepressants. 35 There is preliminary evidence that serotonergic pathways could be implicated in SAMS. In an observational study of 7924 patients with hyperlipidemia receiving high-dosage statin therapy, patients treated with antidepressants had a 50% reduction in SAMS and patients with a history of fibromyalgia-like symptoms were 3 times more likely to experience muscle pain on statins. 8 There are genetic links to support these findings. Variants in the genes that encode for serotonin receptors HTR3B (rs2276307) and HTR7 (rs1935349) are significantly correlated with myalgia scores in statin-treated patients. 36 Thus, there is a rationale to infer that statin-induced myalgia may be mediated by depression or other psychological pathways (ie, anxiety, stress); however, the present study does not provide evidence to support these associations.
Statin-Associated Muscle Symptoms
Because pain is a subjective experience, true SAMS is difficult to distinguish from muscle pain of other origins. Observational studies have reported the prevalence of muscle-associated side effects in statin users to be as high as 60%. 5 However, the present study and other randomized-clinical placebo trials have found the incidence of SAMS to be much lower (ie,~10%). 9, 37 This discordance is most likely because of clinical trials using a more stringent assessment of myalgia with study definitions and the use of a placebo arm to establish a causal relationship (ie, muscle symptoms on statin rechallenge and no muscle symptoms on placebo). 13 It is possible that self-reports of nonspecific muscle symptoms (ie, did not meet the study definition of myalgia) were not captured in the STOMP trial. 9 However, the present study used a low threshold for self-report muscle complaints in a logistic regression model (ie, any changes in pain after 6 months from baseline 91.0 on the BPI scale) and found no changes in pain severity, pain intensity, or pain interference that were influenced by baseline psychological health (Figure 3) . Furthermore, among the individuals within the present substudy who met the study definition for myalgia (n = 7), there were no differences in baseline depression scores (myalgia, 5.14 T 3.5 vs no myalgia, 4.33 T 4.4; P = .663) or psychological well-being (myalgia, 88 T 5.5 vs no myalgia, 88.7 T 15.9; P = .903). This is reassuring for statin prescribing clinicians who treat patients with comorbid depression and/or low psychological wellbeing as baseline psychological health indicators do not appear to mediate changes in muscle pain during statin treatment, even in patients with documented SAMS in a placebo-controlled setting.
Limitations
The present study consists of a post hoc analysis of the larger STOMP trial and thus was not originally powered to examine baseline psychological wellbeing and/or depression on SAMS. However, with 40 participants on atorvastatin and a power of .80, we were powered to detect a difference of 1.04 at an ! of .05, suggesting that negative findings were not due to type II statistical error. A major strength of the present study is that we examined the effect of a single, maximum daily dose of atorvastatin (80 mg) for 6 months versus placebo, thus significantly reducing variability in the statin-associated muscle complaint response. Previous studies have assessed statins of various doses and types, which may contribute to the heterogeneity in the published literature regarding the influence of statins on muscle complaints.
It is also noteworthy to mention that the present population had relatively high levels of psychological well-being and low levels of depression, and this characteristic could explain the lack of association between psychological health indicators and self-reported pain. On average, the study population was classified as ''minimally depressed'' (mean BDI, 4.4 T 4.5). Future studies may consider examining self-reports of muscle complaints before and after statin treatment in a more clinically depressed population.
Clinical Implications
Statins are the most widely prescribed drugs in the United States and the world. 3, 4 Application of the new American College of Cardiology/American Heart Association guidelines on the management of blood cholesterol would increase the number of US adults receiving or eligible for statin therapy from 43.2 million to 56 million, suggesting that the number of statin users will only continue to increase. 4 High rates of statin discontinuation due to muscle complaints (30%Y62%) underscore the need for researchers to better understand individual factors underlying such reports.
5Y7
The clinical consequences of suboptimal statin adherence or discontinuation of a prescribed statin are clinically meaningful. 7 Chowdhury et al 7 observed a 15% increase in CVD related events and a 45% increase in all-cause mortality in statin-using patients taking less than 80% of their prescribed statin therapy versus patients with higher adherence. Thus, the development of a screening tool to better characterize and screen for patients who may be at risk for SAMS is imperative. Presently, suspected risk factors associated with SAMS are high statin dose, lower body mass index, advanced age, female sex, heavy drinking, multisystemic diseases, and heavy exercise. 38 To date, no studies have examined the influence of psychological health parameters on muscle pain reports after statin initiation. The present study provides preliminary data to refute any influence of psychological health on statin-associated muscle pain among healthy adults and focuses future research efforts considerably.
Conclusion
To conclude, baseline psychological health indicators did not appear to predict or influence the onset of muscle pain during 6 months of high-dose statin therapy among a population of healthy adults with generally h Statins are generally well tolerated; however, muscle symptoms can provoke discontinuation, with incidence ranging from 10% to 25% in nonYindustry-funded trials, but as high as 60% in observational studies h Mental health influences self-perception of pain and may partially explain the wide range of prevalence of muscle symptoms in statin users and potentially aid clinicians to screen for patients at-risk for statin myopathy before or during statin treatment h Baseline psychological health indicators (ie, well-being and depression) did not appear to predict or influence the onset of muscle symptoms during 6 months of high-dose statin therapy.
